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ABSTRACT
Melanoma is an aggressive form of skin cancer that is curable by surgical
excision in the majority of cases, if detected at an early stage. To improve early stage
melanoma detection, the development of a highly sensitive diagnostic test is of utmost
importance. Here we aimed to identify antibodies to a panel of tumour associated
antigens that can differentiate primary melanoma patients and healthy individuals.
A total of 245 sera from primary melanoma patients and healthy volunteers were
screened against a high-throughput microarray platform containing 1627 functional
proteins. Following rigorous statistical analysis, we identified a combination of 10
autoantibody biomarkers that, as a panel, displays a sensitivity of 79%, specificity
of 84% and an AUC of 0.828 for primary melanoma detection. This melanoma
autoantibody signature may prove valuable for the development of a diagnostic blood
test for routine population screening that, when used in conjunction with current
melanoma diagnostic techniques, could improve the early diagnosis of this malignancy
and ultimately decrease the mortality rate of patients.

INTRODUCTION

indicating the importance of the timely diagnosis of this
malignancy. A number of diagnostic screening methods
are currently available for the detection of melanoma
and include the visual examination of suspicious lesions
using dermoscopy, reflectance confocal microscopy, total
body photography, teledermatology and mobile phone
applications. However, all of these have limitations,
including their high subject to observer bias. Moreover,
it is questionable whether these methods are suitable for
the screening of people at risk of melanoma development,
such as patients with a substantial number of moles on
their body (>100), those with a family history, cases of

Worldwide, skin cancer remains a major health
concern. The incidence of cutaneous melanoma, the most
aggressive and treatment resistant type of skin cancer,
continues to increase and New Zealand followed by
Australia have the highest incidence rates [1]. Recent data
shows that Australians are four times more likely to develop
a cancer of the skin than any other type of cancer [2].
Detecting the primary melanoma tumours at an early stage
results in a 5-year survival rate as high as 99%, whereas
5-year survival for late stage patients is only 15–20% [3],
www.oncotarget.com
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in situ, I or II) and 121 healthy controls. The participant
characteristics are summarised in Table 1. The number
of males was higher than the number of females in both
cohorts and in cohort 1, patients were slightly older
than healthy volunteers (mean and standard deviation
of 62.5 ± 16.3 versus 56.5 ± 12.9 years, p = 0.003).
This was largely due to the difference in age of the male
participants between patients and healthy volunteers (63.7
± 14.7 versus 56.8 ± 13.2 years, p = 0.004). There was no
significant difference in the mean age of female patients
relative to female controls in cohort 1 (59.8 ± 19.4 versus
55.7 ± 12.3 years, p = 0.309).

occult melanoma, or those with very thin and unpigmented
primary lesions [4].
A routine blood test used as an adjunct to currently
utilised diagnostic approaches may enable improved
melanoma screening diagnostic efficiency, especially
in cases for which current diagnostic techniques are
suboptimal. To date, many blood based biomarkers
have been proposed for melanoma prognosis, indication
of recurrence, and assessment of treatment response,
including microRNAs [5], circulating tumour cells [6]
and circulating tumour DNA [7]. However, none of these
appear to be sufficiently sensitive to detect the initial
transformation to malignancy and may therefore not be
suitable diagnostic biomarkers of early stage melanoma.
Autoantibodies (AAbs) may provide a more
advantageous blood based biomarker, as they reflect the
initial humoral immune response against a tumour and their
increased levels can be detectable months to years prior
to clinical evidence of a primary tumour [8]. While the
mechanisms involved in the production of AAbs in cancer
patients (reviewed recently in Zaenker et al. 2016 [9]),
remain speculative, AAbs are well known to be sensitive
biomarkers in the detection and surveillance of many types
of tumours [10–14]. Their diagnostic utility in melanoma,
however, is yet to be conclusively demonstrated.
High-density protein microarrays allow the
functional testing of thousands of proteins simultaneously,
increasing the chance of discovery of new autoantibody
signatures [15]. These microarrays, in which proteins are
immobilised in their natural conformations, enable the
identification of AAb profiles within patient sera [16].
Here we utilised the Immunome™ Protein Array containing
1627 proteins, developed by Oxford Gene Technology,
Oxfordshire, United Kingdom [17], to screen sera from a
total of 124 early stage melanoma patients and 121 healthy
volunteers. We utilised a novel approach to the statistical
analysis of protein microarray data, in order to identify the
most predictive panel of AAbs for melanoma diagnosis.
First, we identified individual autoantibody biomarkers
that were most commonly detectable in the patient cohort.
Then, a random forest and classical classification tree
analysis [18, 19] was performed to identify a panel of 10
autoantibody biomarkers that in combination significantly
differentiated primary melanoma patient sera from healthy
control sera. We further investigated whether patient and
tumour characteristics affected the breadth and magnitude
of the serologic autoantibodies. Finally, we explored AAb
biomarker associated disease related pathways using the
STRING functional protein association network (Figure 1).

Melanoma-associated AAb biomarkers
In cohort 1, a total of 748 antigens were identified
to preferentially react with the patient sera as indicated
by their positive biomarker scores. Of those, 139 resulted
in biomarker scores of greater than 5 and were therefore
considered to have a potential diagnostic value for
melanoma (Supplementary Table 1.2). The majority of the
identified 139 antigens displayed very high specificity,
ranging from 86.7%–100% (mean of 97%), while their
sensitivity as single biomarkers ranged from 2.9% to
18.3% (mean of 9.9%), which is comparable to similar
cancer AAb studies [20, 21]. Notably, 20/139 (14.4%)
antigens did not react with any of the healthy control
samples.
The serum scores of melanoma patients (median
60.5; IQR 33.9–95.9) were significantly higher than
those for healthy controls (median 15.5; IQR 6.7–27.7)
(p < 0.001, Figure 2A). To evaluate the diagnostic
performance of the identified biomarkers in a different
cohort of samples, we calculated the serum scores for the
top 139 biomarkers using the 36 samples included in cohort
2. Patient serum scores were again significantly higher,
with a median of 51.1 (IQR 38.7–77.7) compared to healthy
control median serum score of 38.9 (IQR 14.1–53.7,
p = 0.029, Figure 2B), supporting the validity of the top
139 biomarkers.
Most of the identified markers are novel and are
not known for their association with melanoma. It is
however important to note that many were reactive against
transcription factors, tumour suppressors and promoters,
markers of apoptosis, and regulators of pigmentation
and T-cell differentiation that may influence an array of
cancer-related pathways. Some of the top 139 seroreactive
antigens such as VEGFb, p53, MITF, KIT and MLANA
[22] have previously been associated with melanoma and
cancer in general, indicating that the detected autoantibody
response may be derived from an antitumour response.
The generated STRING protein association network
of the top 139 antigens can be viewed in the Supplementary
Figure 1 and a detailed table containing a short protein
description and interaction scores is summarised in
Supplementary Table 1.3 and Supplementary Table 2.5.

RESULTS
Study cohort
The 245 samples used in the study comprised a
total of 124 early stage melanoma patients (TNM stages
www.oncotarget.com
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AAb biomarker combination

Supplementary Table 2.1, 2.2, 2.3 and 2.4 detail the
biological functions, molecular pathways, cellular location
and KEGG pathways associated with the submitted
list of proteins. Interestingly, most of the seroreactive
proteins are intracellular antigens (101/139), of which
the majority are contained within the nucleus (88/139),
a cellular location that is usually protected from immune
surveillance. Many cancer autoantibody studies have
also reported detection of AAbs against nuclear antigens
and this has been suggested to be due to spillage of the
intracellular contents into the surrounding tissue following
cell death in cancer [9]. Nuclear antigens generally do
not undergo cross-presentation in the negative selection
process of B-cell maturation and may therefore result in
enhanced immune reactions. Furthermore, the top 139
identified biomarkers appear primarily related to general
cancer pathways, including apoptosis, pathways associated
with the immune response and cell cycle, p53 signalling
and the MAPK signalling pathway, the main pathway
associated with melanomagenesis, highlighting the
biological relevance of the identified biomarkers.

Since the development of a diagnostic blood test that
is comprised of 139 biomarkers is impractical and hence
not clinically applicable, we utilised a two stage analysis
approach involving random forest and classification
tree analysis [18, 19] to identify a combination of 10
biomarkers or less with the highest diagnostic potential.
Following random forest analysis of the data
from cohort 1, the top 20 most influential markers for a
diagnostic model were identified, and the most important
AAbs were given a rank score of 20 and the least important
marker a score of 1. This analysis was repeated 1000 times
to generate 1000 random forests. When the top 20 markers
of each of these 1000 forests were combined, a list of
27 unique biomarkers and their percent model inclusion
frequency and average rank scores, were identified. The
proportion of the appearance of each of these biomarkers
in the 1000 top 20 AAb lists were then multiplied by
the average rank score to obtain a weighted mean rank
by which the overall importance of the biomarker for
melanoma diagnosis was determined. In cohort 1, patient

Figure 1: Study design flowchart.
www.oncotarget.com
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Table 1: Clinicopathological characteristics of the study participants
Group
total cohort number
sample number
Female, n (%)
Male, n (%)
Mean age ± SD (years)
Age range (years)
TNM stage, n (%)
0 (in situ)
I
II
Site of primary tumour, n (%)
Head and Neck
Trunk
Extremities
Multiple primary melanoma with
multiple tumour sites
Melanoma subtype, n (%)
SSM
NM
LMM
ALM
unclassified
not reported
Breslow thickness, n (%)
≤1 mm
1-2 mm
2-4 mm
4+ mm
Clark level, n (%)
1
2
3
4
5
Ulceration, n (%)
present
absent
not reported
Mitotic rate, n (%)
≤1 mm²
1-5 mm²
5-10 mm²
10+ mm²
not reported
www.oncotarget.com

Cohort 1
Early-stage CM
Healthy
patients
volunteers
104
32 (30.8)
72 (69.2)
62.5 ± 16.3
20–96

209

105
35 (33.3)
70 (66.7)
56.5 ± 12.9
20–83

Cohort 2
Early-stage CM
Healthy
patients
volunteers
20
5 (25.0)
15 (75.0)
57.2 ± 13.5
26–76

45 (43.3)
39 (37.5)
20 (19.2)

15 (75.0)
5 (25.0)
0 (0.0)

16 (15.4)
41 (39.4)
44 (42.3)

4 (20.0)
8 (40.0)
8 (40.0)

3 (2.9)

0 (0.0)

19 (18.3)
10 (9.6)
8 (7.7)
0 (0.0)
26 (25.0)
41 (39.4)

4 (20.0)
0 (0.0)
0 (0.0)
0 (0.0)
9 (45.0)
7 (35.0)

77 (74.0)
11 (10.6)
9 (8.7)
7 (6.7)

20 (100.0)
0 (0.0)
0 (0.0)
0 (0.0)

44 (42.3)
21 (20.2)
12 (11.5)
26 (25.0)
1 (1.0)

14 (70.0)
3 (15.0)
2 (10.0)
1 (5.0)
0 (0.0)

22 (21.2)
65 (62.5)
17 (16.3)

3 (15.0)
14 (70.0)
3 (15.0)

69 (66.3)
12 (11.5)
6 (5.8)
4 (3.9)
13 (12.5)

16 (80.0)
0 (0.0)
0 (0.0)
0 (0.0)
4 (20.0)
30542
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16
3 (18.8)
13 (81.2)
55.8 ± 13.4
25–80
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Regression, n (%)
present
39 (37.5)
8 (40.0)
absent
28 (26.9)
4 (20.0)
not reported
37 (35.6)
8 (40.0)
History of multiple CM, n (%)
Yes
26 (25.0)
5 (25.0)
No
77 (74.0)
14 (70.0)
not reported
1 (1.0)
1 (5.0)
History of NMSC, n (%)
Yes
33 (31.7)
6 (30.0)
No
67 (64.4)
9 (45.0)
not reported
4 (3.9)
5 (25.0)
History of other cancer, n (%)
Yes
10 (9.6)
1 (5.0)
No
87 (83.7)
14 (70.0)
not reported
7 (6.7)
5 (25.0)
Numbers are rounded to 1 decimal; SD, standard deviation; CM, cutaneous melanoma; NMSC, non-melanoma skin
cancer; SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo maligna melanoma; ALM, acral
lentiginous melanoma

Figure 2: (A) Dot plot of melanoma patient and healthy control serum scores for the top 139 individual melanoma-associated biomarkers

in cohort 1, the horizontal lines represent the median and IQR of all serum scores in each cohort, dots represent individual samples.
(B) Dot plot of melanoma patient and healthy control serum scores for the top 139 individual melanoma-associated biomarkers in cohort 2.
www.oncotarget.com
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serum scores for these 27 antigens were again significantly
higher with a median of 10.2 (IQR 4.7–19.1), than the
healthy control median serum score of 0 (IQR 0–1.6,
p < 0.0001, Figure 3A). However, there was no significant
difference between patient and controls serum scores
in cohort 2 (median of 11.2 (IQR 6.2–22.0) versus 5.5
(1.4–16.9), p = 0.176, Figure 3B), possibly due to the small
sample size. Interferon regulator 4 (IRF4) was the most
frequently included biomarker in the 1000 combinations
and displayed the highest average rank score and was
therefore the most important marker to contribute to the
overall sensitivity and specificity in a combination of
AAbs. As a single biomarker, IRF4 displayed a sensitivity
of 5.8% at 100% specificity.
Classification tree analysis was then applied to these
27 biomarkers and showed that the best combination of
biomarkers ensuring an increased combined sensitivity

and specificity for melanoma diagnosis, is a signature of
10 AAbs, including in order, ZBTB7B, PRKCH, TP53,
PCTK1, PQBP1, UBE2V1, IRF4, MAPK8_tv2, MSN
and TPM1, with a sensitivity of 79%, specificity of 84%
and an AUC of 0.828 (Figure 4A–4C). The biomarkers
included in the panel did not necessarily display the
highest individual diagnostic potential (Supplementary
Table 1.2). Instead, they are a combination, displaying a
broader occurrence of positive seroreactivity for patient
sera if a positive diagnosis is said to be represented by
positive seroreactivity with at least one of the biomarkers
in the combination.

Breadth of autoantibody responses
The breadth of AAb responses against the protein
microarray of 1627 proteins varied between samples.

Figure 3: (A) Dot plot of melanoma patient and healthy control serum scores for the 27 melanoma-associated biomarkers with the highest
weighted mean rank (WMR) score in cohort 1. (B) Dot plot of melanoma patient and healthy control serum scores for the 27 melanomaassociated biomarkers with the highest weighted mean rank (WMR) score in cohort 2.
www.oncotarget.com
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Patient characteristics

Positive autoantibody production in a sample was defined
as a fluorescence reading above the protein associated
cutoff. Positive autoantibody production to at least one
of the proteins was observed in every study participant
sample in cohort 1. Out of the 1627 antigens on the array,
patient sera reacted with a median of 46.0 (IQR 36.0–70.0)
antigens while healthy control sera reacted with a median
of 48.0 (IQR 40.5–57.0) antigens (p = 0.857). All patient
samples and 92.4% of healthy control samples reacted
with at least one of the top 139 antigens. In total, a sum
of 1426 positive antibody responses against the top 139
antigens were observed in the 104 patients while only
434 positive antibody responses were observed in the
105 healthy controls. A statistically significant difference
was observed between the number of individual patient
and healthy control sample AAb responses against the
139 antigens (median of 9.0 (IQR 6.0–22.0) versus 3.0
(IQR 1.0–4.0), respectively, p < 0.001). The median
number of AAb responses was also significantly different
between patient and healthy control samples (p < 0.001)
for the identified AAb biomarker combination of 10
autoantibodies, with patient samples displaying a median
of 1.0 (range 0–3.0) when compared the control median
of 0 (range 0–2.0).

Similar to other studies, we did not observe any
significant differences or correlations in serum score
or frequency of positive AAb reactions against the top
139 antigens when comparing age, gender, TNM stage,
site of primary tumour, melanoma subtype, Breslow
thickness, ulceration, mitotic rate, and history of multiple
melanomas, non-melanoma skin cancers or other cancers
(Supplementary Table 1.4). We did however observe a
significantly lower number of AAb responses in patients
with histologic regression features in their primary tumour
than those who did not display features of regression
(median and IQR of 7 (5.0–13.0) versus 11.5 (7.0–29.8),
p = 0.010).

DISCUSSION AND CONCLUSIONS
The benefit of early melanoma detection and
timely surgical excision of the primary tumour is clear.
Despite advances in diagnostic methods, screening large
populations for melanoma remains inefficient due to
the time required to screen each individual and due to a
plethora of other limitations clinicians face in the current

Figure 4: (A) Regression tree diagram of the best combination of the identified autoantibody biomarkers. (B) Cumulative sensitivity and
specificity of the 10 AAb biomarker panel. (C) ROC curve and AUC of the biomarker combination in cohort 1.
www.oncotarget.com
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diagnosis of this cancer [4]. In particular, while individuals
in countries with a high melanoma prevalence such as
Australia and New Zealand are advised to maintain routine
annual skin checks, there is no capacity for this practice
given the limited number of dermatologists available in
the country, especially in the rural regions in Australia
[23]. Complementary diagnostic tools, such as blood tests,
are needed to increase melanoma screening efficiency,
provide diagnostic certainty and lower the overemphasis
on invasive and expensive biopsies [24]. In fact, previous
data has shown that only 5% of the total health care costs
associated with melanoma are spent on the management
of early melanoma disease including the costs of primary
tumour diagnosis and excision, while the remaining 95%
of all melanoma related health care costs are spent on the
treatment and management of advanced melanoma [25],
estimated to amount to $201 million annually in Australia
[26]. Therefore, early detection and treatment could not
only drastically improve patient 5-year survival rates to
99% [3], but also lower the financial burden of the disease
on the health care system.
As blood samples are easily accessible from patients,
various types of blood-based biomarkers have already been
proposed to be utilised in a blood test for melanoma [5–7,
27], but none have yet demonstrated sufficient sensitivity
to detect biological changes at the earliest stages of
this malignancy. AAbs that bind to tumour-associated
autoantigens, rise in serum levels at early disease stages,
possibly due to a change in their expression, structural
confirmation, presence of mutations or their release into the
surrounding blood serum due to cancer cell lysis [9]. AAbs
have already been shown to reside within the patient’s
blood months to years prior to the clinical manifestation of
the primary tumour [8, 28]. They have also been proposed
to be valuable biomarkers for the early detection of many
types of cancers and some are already being utilised in
current diagnostic tests such as the EarlyCDT-Lung test
for lung cancer detection and PAULA’s test for non-small
cell lung cancer diagnosis [21, 29, 30]. In melanoma, AAbs
have been suggested to be suitable prognostic biomarkers
[31, 32], however very few studies have detailed their
efficacy. In one study of an AAb signature for gastric
cancer diagnosis, Zayakin and colleagues identified antiDDX53, anti-MAGEA3 and anti-MAGEC1 antibodies
in two samples with advanced melanoma that were
subsequently excluded from further analysis [20].
Notably, few studies have investigated the presence
of AAbs in early stage melanoma [17, 32] and those that
have, commonly investigate the presence of AAbs against
a list of common melanoma-associated targets compiled
from a search of the literature, screen a pool of samples
or utilise cell lines without performing rigorous screening
of the individual patient autoimmune repertoire against an
unbiased array of proteins. Hence to our knowledge, this is
the first study identifying AAbs as diagnostic biomarkers
in a large cohort of primary melanoma patients compared
www.oncotarget.com

to healthy volunteers using a high-throughput functional
protein microarray platform.
There are still no standardized guidelines for the
analysis of protein microarray data. The approach stated
by Gnjatic and colleagues, allowing the identification of
biomarkers based not only on their fluorescent intensity
levels but also their occurrence of positive seroreactivity
in patients versus controls [17], appears to be utilised most
frequently [33]. Using this approach in this study, we have
successfully identified 139 potential melanoma diagnostic
AAb biomarkers with individual sensitivity and specificity
comparable to similar AAb studies [21]. Interestingly, most
of the identified markers are novel and not known for their
association with melanoma but are reactive against nuclear
antigens such as transcription factors that may significantly
influence cancer-related pathways. The inclusion of
previously identified melanoma or cancer associated
biomarkers such as VEGFb, p53, BAD, KIT MITF and
MLANA [22] in the top 139 antigen list, further highlights
the validity of our findings. Histologic tumour regression
status significantly affected the number of positive AAb
responses but although the correlation between regression
and patient outcome has been investigated extensively,
whether the presence of histologic regression features have
a good or bad prognostic significance remains controversial
and is to be elucidated [34]. Autoantibody responses were
not affected by any other patient characteristic or tumour
feature.
Most serum AAbs used as stand-alone diagnostic
assays, show insufficient sensitivity and/or specificity
to be utilised as accurate screening tools [35] and hence
it is the combination of multiple reactive AAbs into a
panel assay which provides the increased sensitivity
and specificity. This approach has been successfully
validated in several independent populations of various
cancer types [36–39] as well as in this cohort of primary
melanoma patients. To identify such combinations, here
we proposed an analysis pipeline including random forest
and decision tree analysis that adds to methods utilised
by Gnjatic et al. 2009 [17], and enabled the identification
of a 10 autoantibody biomarker signature with 79%
sensitivity at 84% specificity for primary melanoma. One
of these biomarkers is IRF4, a known lymphocyte specific
transcription factor that negatively regulates Toll-like
receptor (TLR) signalling, crucial for the activation of both
the innate and adaptive immune response. Additionally,
tumour suppressor p53 was included in the combination.
In fact, the majority of research on autoantibodies in
cancer has been focussed on p53 autoantibodies whose
levels are commonly found to increase with cancer
progression [40, 41], but are also detectable at early stages
as in this study.
Although this analysis repeatedly showed that the
best combination for melanoma diagnosis in our cohort
is the identified signature of 10 AAbs, it is important
to remember that there may be many other possible
30546
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combinations of biomarkers generated using the list of
139 top antigens that may prove valuable for melanoma
detection and should be investigated in the future. Most
importantly, the panel identified here must be validated
using larger cohorts of melanoma patients and should
include patients with other types of cancer or autoimmune
diseases to ascertain whether the combination is melanoma
specific. This may be performed using alternate highthroughput platforms for the simultaneous testing of these
antigens against a vast number of samples to detect AAb
levels, such as the bead-based Luminex platform.
Finally, since it is known that autoantigens that are
modified before or during the course of tumour formation
and progression in cancer, can stimulate the immune
response in patients when they are released from tumour
cells [42] and that immune responses have been observed
to be responsible for tumour growth promotion, but also
prevention in a process called immunoediting [43, 44],
the fact that some of the top 139 biomarker associated
signalling pathways are involved in the immune response,
is consistent with the immunoediting theory [43] and leads
to the proposal that the identified AAb biomarkers may
be utilised in future therapeutic interventions to treat or
monitor advanced melanoma and aid in the early diagnosis
and surveillance of patients with melanoma.

tumour diagnosis and excision, some samples were
obtained within a maximum of 3 months of diagnosis.
Venous blood from all study participants was collected into
one 8.5 ml serum separator tube (SST) (BD, New Jersey,
United States). The blood was allowed to clot at room
temperature for a minimum of 30 minutes and centrifuged
at 1600 g for 10 mins. A small number of healthy
volunteer samples (n = 8) which had been collected into
EDTA tubes were analysed from plasma. These samples
were included in this study as serum and plasma samples
have previously been found to yield comparable results
in functional protein microarray studies [17]. Following
centrifugation, serum was aliquoted as soon as possible
but within 24 hours and stored at −80° C.

Protein microarray profiling
The functional protein microarray was developed
and constructed by Oxford Gene Technology (OGT),
Oxfordshire, United Kingdom, as described previously
[17]. Patient or control serum samples were diluted
1:200 in 2 ml buffer (0.1% Triton X100 (v/v), 0.1%
BSA (w/v) in PBS) and applied to the array (one array
per sample). The arrays were incubated in Quadriperm
dishes (Greiner BioOne, Stonehouse, UK) and placed on
a horizontal shaker at 50 rpm for a period of 2 hours at
room temperature. After several washes, anti-human IgG
was diluted 1:1000 in assay buffer and Cy3-rabbit antihuman IgG (Dako Cytomation) by incubation for 2 hours
at room temperature according to the manufacturer´s
recommendations. The array was washed again and dried
by centrifugation. All arrays were scanned at 10 µm
resolution using a microarray scanner (Axon 4200AL with
GenePix Pro Software, Molecular Devices, Sunnyvale,
CA, USA) and fluorescence of labelled IgG was detected
according to the manufacturer’s instructions. Images were
saved as 16-bit tiff files and analysis was performed using
GenePix software [17]. Interaction between microarray
antigens and serum autoantibodies was detected as
fluorescence of the bound fluorescently-labelled IgG
at the protein specific position on the microarray. The
intensity of fluorescence is proportional to the amount
of autoantibody present in the serum [17, 45]. Local
background obtained from control spots on the array was
subtracted automatically and relative fluorescence units
(rfu) for each microarray spot were recorded. Each antigen
was immobilised in quadruplicate on the array. The median
rfu for the four readings of each antigen was utilised for
further analysis. A reference serum was included in each
microarray experiment run. Arrays that did not pass quality
control tests were repeated or the spots were realigned in
the software or excluded. Thereafter, arrays were excluded
from the analysis if they did not pass quality control.
Samples were tested by Sengenics, University of
Malaysia, Kuala Lumpur, Malaysia, for the microarray
screening of cohort 1 or by Oxford Gene Technology

MATERIALS AND METHODS
Study participants
A total of 245 study participants were recruited
by collaborating clinicians and the principal researchers
(minimum sample size required per group to achieve at
least an AUC of 0.66 at an alpha of 0.05 and 80% power
is n = 47 per group). All participants provided informed
consent to participate in this study, previously approved by
the Edith Cowan University Ethics Committee (numbers
11543 and 12066). Patients were diagnosed by routine
pathological examination of their excised primary tumour
and staged according to the TNM staging system for
melanoma according to the American Joint Committee on
Cancer (AJCC) guidelines [3]. Healthy volunteers were
defined as never having been diagnosed with melanoma,
any other type of cancer or any autoimmune disease. The
study cohort 1 consisted of 104 early stage melanoma
patients (classified as TNM stages in situ, I and II) and 105
healthy volunteers. A smaller cohort including 20 early
stage melanoma patients (classified as TNM stages in situ
and I only) and 16 healthy volunteers (cohort 2) was also
utilised for validation.

Sample collection
A once-off blood sample was obtained from all
study participants. For the majority of melanoma patients,
the sample was obtained within 1 month of patient primary
www.oncotarget.com
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Selection of biomarker panel

(OGT), Oxfordshire, United Kingdom, for the microarray
screening of cohort 2. Both locations utilised the same
Immunome™ microarray platform (Sengenics). OGT
and Sengenics staff were blinded to the fact that, for the
purpose of cross-validation between the two screening
sites, identical aliquots from 16 randomly selected patients
and 11 healthy control samples were screened at both sites,
and showed comparable results (Spearman rho > 0.5,
Supplementary Table 1.1) enabling the use of cohort 2 as
an independent validation cohort.

The analysis proposed here furthers the methodology
proposed by Gnjatic et al. 2009 [17] by subsequently
exploring combinations of identified biomarkers for early
melanoma detection, rather than individual biomarkers,
to achieve increased combined sensitivity and specificity.
The classification tree method was selected for this task
and this analysis was performed using data from cohort
1 only as cohort 2 was not sufficiently powered. The
number of variables (i.e. 139 antigens) at this stage was
still reasonably large relative to the overall sample size.
To avoid the possibility of overfitting, a two-stage process
was utilised, as follows:
Stage l involved the use of random forest regression
analysis [18] for identifying key biomarker proteins and
to further reduce the number of biomarkers in contention
for the next modelling stage. Stage 2 utilised the classical
classification tree approach [19] to develop a tree model
based on the reduced list of biomarkers.
All analyses were implemented with the R software
package (Version 3.2.2). The key R packages used were
randomForest [47] (based on the original Fortran code by
Breiman and Cutler), rpart [48] and caret [49].

Statistical analysis
Data normalisation
Intra- and inter-array data normalisation was
performed to ensure data comparability between samples.
First, the overall median value of all median rfu values of
the 1627 printed proteins (excluding data from controls
spots) was calculated and intra-array normalisation was
achieved by dividing the median of the quadruplicate
spots of each protein on the array, by the overall median
value of all the proteins on the array in each sample. Interarray normalisation was achieved by utilisation of the
normalize.quantiles package [46] in R.

Additional statistical analysis

Selection of melanoma associated autoantibodies

The previously established antigen-associated cutoffs
were, additionally, used to determine (1) the number of
positive AAbs (i.e. above the cutoffs) and (2) the serum
score for each sample. The “serum score” is the sum of all
signal intensities above the said cutoffs. To test whether
these data were approximately normally distributed, a
Shapiro-Wilk’s test (p > 0.05) [50], visual inspection
of histograms, normal Q-Q plots and box-plots were
performed. As the majority of the data in this study were
not normally distributed, non-parametric methods were
utilised. The Mann–Whitney U test was used to test for
differences in serum scores between patients and controls.
Spearman rho correlation analysis was used to test for a
statistical relationship between patient age, tumour Breslow
thickness and mitotic rate with the number of positive
AAbs and patient serum scores. Differences in patient
serum score or the number of positive AAbs with regards
to gender, tumour ulceration, histologic regression, history
of multiple diagnosed melanoma in the patient’s lifetime, a
history of non-melanoma skin cancer or other cancer were
assessed by Mann–Whitney U test. Serum score or number
of positive AAb differences with regards to tumour TNM
stage, primary tumour site, melanoma subtype and Clark
level were assessed by Kruskal-Wallis analysis. Sensitivity
and specificity of individual and combinations of AAbs
were evaluated by ROC. These analyses were performed
using Microsoft Excel, IBM SPSS statistical software
(version 22.0) and GraphPad Prism (version 5). A p-value
of < 0.05 was defined as statistically significant.

Once normalised, data analysis was performed
as described by Gnjatic et al. 2009 [17] to determine
the proteins with the highest and most frequent
seroreactivity in patient samples relative to healthy
volunteer sera. For this, the interquartile range (IQR)
was calculated for each protein to establish a cutoff.
This cutoff (2.5 × IQR above the 75th percentile) was
used to dichotomise the data, whereby a value was
defined as positive (for seroreactivity) if it was above
the cutoff; otherwise it was defined as negative. This
criterion was used to ensure false positive data was
minimised while providing increased specificity and
sensitivity [17]. For cases with positive seroreactivity,
the ratio between the signal and cutoff (S/C ratio)
was calculated. Thereafter, the average S/C ratio was
calculated per protein for each cohort, i.e. melanoma
patient or healthy control.
Finally, a “biomarker score” was assigned to each
protein by multiplying the number of positive samples
by the cubic root of the corresponding S/C ratio average
for each cohort. This score is a reflection of the strength
and frequency of the signal in patients relative to healthy
subjects. The proteins were then ranked based on the
differences in the biomarker scores (patients–healthy
controls). A large AAb biomarker score (>5) indicates
that most seroreactivity is attributable to the patients [17].
This reduced the number of potential diagnostic melanoma
autoantibody biomarkers from 1627 to 139 in cohort 1
(Supplementary Table 1.2).
www.oncotarget.com
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Finally, to explore the biological relevance of the
identified autoantibody biomarkers and their interactions,
we submitted the top 139 antigen names to the online
functional protein association network, STRING, to
explore the main shared antigen pathways at medium
protein interaction confidence of 0.400. The submitted
protein names are identical to Supplementary Table 1.2
while protein PCTK1 and SDCCAD10 were searched by
their alternative names CDK16 and CWC27, respectively.

author PZ received ongoing financial support as part of
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University. EG is supported by a fellowship from the
Cancer Research Trust.

REFERENCES
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014.
CA Cancer J Clin. 2014; 64:9–29. https://doi.org/10.3322/
caac.21208.

Abbreviations

2. Ong E, Goldacre R, Hoang U, Sinclair R, Goldacre
M. Subsequent primary malignancies in patients with
nonmelanoma skin cancer in England: A national recordlinkage study. Cancer Epidemiol Biomarkers Prev. 2014;
23:490–8. https://doi.org/10.1158/1055-9965.EPI-13-0902.

AAbs: autoantibodies; AJCC: American Joint
Committee on Cancer; SST: serum separator tube; OGT:
Oxford Gene Technology; rfu: relative fluorescence units;
AUC: area under the curve; ROC: receiver operating curve;
IQR: inter quartile range; SSM: superficial spreading
melanoma; NM: nodular melanoma; LMM: lentigo
maligna melanoma; ALM: acral lentiginous melanoma.

3. Balch CM, Gershenwald JE, Soong S, Thompson JF,
Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, Eggermont AM, Flaherty KT, Gimotty PA, et
al. Final Version of 2009 AJCC Melanoma Staging and
Classification. J Clin Oncol. 2009; 27:6199–206. https://
doi.org/10.1200/JCO.2009.23.4799.

Author contributions

4. Loescher LJ, Janda M, Soyer HP, Shea K, CurielLewandrowski C. Advances in skin cancer early detection
and diagnosis. Semin Oncol Nurs. 2013; 29:170–81. https://
doi.org/10.1016/j.soncn.2013.06.003.

All authors have contributed to the conception
and design of the study, acquisition of data, or analysis
and interpretation of data. The authors PZ, JL, EG and
MZ have been involved with the drafting of the article
and revising its important content. All listed authors have
approved the final version of the submitted article.

5. Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang
YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ,
Thompson JF, Long GV, Barbour AP, et al. The prognostic
and predictive value of melanoma-related microRNAs
using tissue and serum: a microRNA expression analysis.
EBioMedicine. 2015; 2:671–80. https://doi.org/10.1016/j.
ebiom.2015.05.011.

ACKNOWLEDGMENTS
We would like to thank Sengenics and Oxford Gene
Technology for their microarray screening service of our
described cohorts. We would thank Dr. Jenny Conlon for
her help in collecting some of the healthy volunteer blood
samples. We would also like to extend our thanks to Mrs.
Liz Watson for her unwavering support and the collection
of new blood samples from Professor Pearce’s patients.
We would also like to thank all participants and all other
clinicians, including Dr. R. Haston, Dr. G. Potter, Dr. T.
Kurdian, Dr. J. Flynn, Dr. J. Chan, Dr. H. Hankey. Dr. J.
Rohr, Dr. E. Stewart, Dr. J. Wang, Dr. S. Lo, Dr. G. Thom,
Dr. A. Zentner, Clin. A./Prof. K. Gebauer, Dr. T. Delaney
Greebwood, Dr. M. Hanikeri and Dr. D. McCann, without
whom this study would not have been possible.

6. Freeman JB, Gray ES, Millward M, Pearce R, Ziman
MR. Evaluation of a multi-marker immunomagnetic
enrichment assay for the quantification of circulating
melanoma cells. J Transl Med. 2012; 10:192. https://doi.
org/10.1186/1479-5876-10-192.
7. Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J,
Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma
C, Cooper A, et al. Circulating tumor DNA to monitor
treatment response and detect acquired resistance in patients
with metastatic melanoma. Oncotarget. 2015; 6:42008–18.
https://doi.org/10.18632/oncotarget.5788.
8. Anderson KS, LaBaer J. The sentinel within: exploiting the
immune system for cancer biomarkers. J Proteome Res.
2005; 4:1123–33. https://doi.org/10.1021/pr0500814.

CONFLICTS OF INTEREST

9. Zaenker P, Gray ES, Ziman MR. Autoantibody Production in
Cancer - The Humoral Immune Response toward Autologous
Antigens in Cancer Patients. Autoimmun Rev. 2016; 15:477–
83. https://doi.org/10.1016/j.autrev.2016.01.017.

The authors of the manuscript declare no conflict
of interest.

FUNDING

10. Diesinger I, Bauer C, Brass N, Schaefers HJ, Comtesse N,
Sybrecht G, Meese E. Toward a more complete r ecognition of
immunoreactive antigens in squamous cell lung carcinoma. Int
J Cancer. 2002; 102:372–78. https://doi.org/10.1002/ijc.10714.

This project was funded by an NHMRC
Development grant (APP1076172) to MZ and EG. The
www.oncotarget.com

30549

Oncotarget

11. Luna Coronell JA, Syed P, Sergeien K, Gyurján I,
Weinhäusel A. The current status of cancer biomarker
research using tumor-associated antigens for minimal
invasive and early cancer diagnostics. J Proteomics. 2012;
76:102–15. https://doi.org/10.1016/j.jprot.2012.07.022.
12. Syed P, Vierlinger K, Kriegner A, Sergeien K. Evaluation
of auto-antibody serum biomarkers for breast cancer
screening and in silico analysis of sero-reactive proteins. J
Mol Biochem. 2012; 1:116–28.
13. Qian F, Odunsi K, Blatt LM, Scanlan MJ, Mannan M, Shah N,
Montgomery J, Haddad F, Taylor M. Tumor associated
antigen recognition by autologous serum in patients with
breast cancer. Int J Mol Med. 2005; 15:137–44. https://doi.
org/10.3892/ijmm.15.1.137.
14. Vaughan HA, St Clair F, Scanlan MJ, Chen YT,
Maraskovsky E, Sizeland A, Old LJ, Cebon J. The humoral
immune response to head and neck cancer antigens as
defined by the serological analysis of tumor antigens
by recombinant cDNA expression cloning. Cancer
Immun. 2004; 4:5–20. http://www.cancerimmunity.org/
v4p5/040505.htm.
15. Ramachandran N, Raphael JV, Hainsworth E, Demirkan
G, Fuentes MG, Rolfs A, Hu Y, LaBaer J. Next-generation
high-density self-assembling functional protein arrays.
Nat Methods. 2008; 5:535–38. https://doi.org/10.1038/
nmeth.1210.

22. Murphy MJ. Diagnostic and Prognostic Biomarkers
and Therapeutic Targets in Melanoma. In: Murphy MJ,
editor. Current Clinical Pathology. Farmington, CT, USA:
Springer. 2012.
23. Chen SC, Pennie ML, Kolm P, Warshaw EM, Weisberg EL,
Brown KM, Ming ME, Weintraub WS. Diagnosing and managing cutaneous pigmented lesions: primary care physicians
versus dermatologists. J Gen Intern Med. 2006; 21:678–82.
https://doi.org/10.1111/j.1525-1497.2006.00462.x.
24. Goldsmith SM. Cost analysis suggests overemphasis
on biopsy rate for melanoma diagnosis. J Am Acad
Dermatol. 2013; 68:517–9. https://doi.org/10.1016/j.
jaad.2012.10.054.
25. Durbec F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F,
Hédelin G, Dalac S, Truchetet F, Michel C, Batard ML,
Domissy-Baury B, Halna JM, Schmutz JL, et al. The role
of circumstances of diagnosis and access to dermatological
care in early diagnosis of cutaneous melanoma: a population-based study in France. Arch Dermatol. 2010; 146:
240–46. https://doi.org/10.1001/archdermatol.2010.10.
26. Elliott TM, Whiteman DC, Olsen CM, Gordon SG. Estimated
health care costs of melanoma in Australia over 3-years
post diagnosis. Appl Health Econ Health Policy. 2017; 15:
805–16. https://doi.org/10.1007/s40258-017-0341-y.
27. Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren
A, Dobrovic A. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet
digital PCR for BRAF and NRAS mutations. Sci Rep. 2015;
5:11198. https://doi.org/10.1038/srep11198.

16. Babel I, Barderas R, Díaz-Uriarte R, MartínezTorrecuadrada JL, Sánchez-Carbayo M, Casal JI.
Identification of tumor-associated autoantigens for the
diagnosis of colorectal cancer in serum using high density
protein microarrays. Mol Cell Proteomics. 2009; 8:2382–
95. https://doi.org/10.1074/mcp.M800596-MCP200.
17. Gnjatic S, Wheeler C, Ebner M, Ritter E, Murray A, Altorki
NK, Ferrara CA, Hepburne-Scott H, Joyce S, Koopman
J, McAndrew MB, Workman N, Ritter G, et al. Seromic
analysis of antibody responses in non-small cell lung cancer
patients and healthy donors using conformational protein
arrays. J Immunol Methods. 2009; 341:50–58. https://doi.
org/10.1016/j.jim.2008.10.016.
18. Breiman L. Random Forests. Mach Learn. 2001; 45:5–32.
https://doi.org/10.1023/A:1010933404324.
19. Breiman L, Friedman J, Stone CJ, Olsen RA. Classification
and regression trees. Belmont, California, USA: Wadsworth.
1984.
20. Zayakin P, Ancāns G, Siliņa K, Meistere I, Kalniņa Z,
Andrejeva D, Endzeliņš E, Ivanova L, Pismennaja A,
Ruskule A, Doniņa S, Wex T, Malfertheiner P, et al. Tumorassociated autoantibody signature for the early detection of
gastric cancer. Int J Cancer. 2013; 132:137–47. https://doi.
org/10.1002/ijc.27667.
21. Zaenker P, Ziman MR. Serologic autoantibodies as diagnostic
cancer biomark ers—a review. Cancer Epidemiol Biomarkers
Prev. 2013; 22:2161–81. https://doi.org/10.1158/1055-9965.
EPI-13-0621.
www.oncotarget.com

28. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR,
Krasnoselsky AL, Randolph TW, Omenn GS, Edelstein C,
Barnett MJ, Thornquist MD, Goodman GE, et al. Occurrence
of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in
prediagnostic lung cancer sera. J Clin Oncol. 2008; 26:5060–
6. https://doi.org/10.1200/JCO.2008.16.2388.
29. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C,
Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, ParsyKowalska CB, MacDonald IK, Jewell W, Maddison P,
Robertson JF. EarlyCDT-Lung test: improved clinical utility
through additional autoantibody assays. Tumour Biol. 2012;
33:1319–26. https://doi.org/10.1007/s13277-012-0379-2.
30. Doseeva V, Colpitts T, Gao G, Woodcock J, Knezevic
V. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med. 2015; 13:55. https://doi.org/10.1186/
s12967-015-0419-y.
31. Sabel MS, Liu Y, Griffith KA, He J, Xie X, Lubman
DM. Clinical utility of serum autoantibodies detected by
protein microarray in melanoma. Int J Proteomics. 2011;
2011:413742. https://doi.org/10.1155/2011/413742.
32. Zörnig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C,
Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M,
Grabe N, Ugurel S, Schadendorf D, Falk C, et al. Prognostic
significance of spontaneous antibody responses against
tumor-associated antigens in malignant melanoma patients.
30550

Oncotarget

Int J Cancer. 2015; 136:138–51. https://doi.org/10.1002/
ijc.28980.
41.

33. Li L, Chen SH, Yu CH, Li YM, Wang SQ. Identification
of hepatocellular-carcinoma-associated antigens and
autoantibodies by serological proteome analysis combined
with protein microarray. J Proteome Res. 2008; 7:611–20.
https://doi.org/10.1021/pr070525r.

42.

34. Aung PP, Nagarajan P, Prieto VG. Regression in primary
cutaneous melanoma: etiopathogenesis and clinical significance. Lab Invest. 2017; 97:657–68. https://doi.org/10.1038/
labinvest.2017.8.
35. Desmetz C, Mange A, Maudelonde T, Solassol J.
Autoantibody signatures: progress and perspectives for
early cancer detection. J Cell Mol Med. 2011; 15:2013–24.
https://doi.org/10.1111/j.1582-4934.2011.01355.x.

43.

36. Goodell V, Salazar LG, Urban N, Drescher CW, Gray H,
Swensen RE, McIntosh MW, Disis ML. Antibody immunity
to the p53 oncogenic protein is a prognostic indicator in
ovarian cancer. J Clin Oncol. 2006; 24:762–8. https://doi.
org/10.1200/JCO.2005.03.2813.

44.

45.

37. Wang X, Yu J, Sreekumar A, Varambally S, Shen R,
Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG,
Kantoff PW, Rubin MA, Wei JT, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353:1224–35.
https://doi.org/10.1056/NEJMoa051931.

46.

38. Wu L, Chang W, Zhao J, Yu Y, Tan X, Su T, Zhao L, Huang
S, Liu S, Cao G. Development of autoantibody signatures
as novel diagnostic biomarkers of non-small cell lung
cancer. Clin Cancer Res. 2010; 16:3760–8. https://doi.
org/10.1158/1078-0432.CCR-10-0193.
39. Chang W, Wu L, Cao F, Liu Y, Ma L, Wang M, Zhao D, Li P,
Zhang Q, Tan X, Yu Y, Lou Z, Zhao J, et al. Development of
autoantibody signatures as biomarkers for early detection of
colorectal carcinoma. Clin Cancer Res. 2011; 17:5715–24.
https://doi.org/10.1158/1078-0432.CCR-11-0199.
40. Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM,
LaBaer J, Cramer D. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.

www.oncotarget.com

47.
48.
49.
50.

30551

Cancer Epidemiol Biomarkers Prev. 2010; 19:859–68.
https://doi.org/10.1158/1055-9965.EPI-09-0880.
Soussi T. p53 antibodies in the sera of patients with various
types of cancer: a review. Cancer Res. 2000; 60:1777–88.
https://cancerres.aacrjournals.org/content/60/7/1777.fulltext.pdf.
Barderas R, Babel I, Díaz-Uriarte R, Moreno V, Suárez
A, Bonilla F, Villar-Vázquez R, Capellá G, Casal JI.
An optimized predictor panel for colorectal cancer
diagnosis based on the combiation of tumor-associated
antigens obtained from protein and phage microarrays. J
Proteomics. 2012; 75:4647–55. https://doi.org/10.1016/j.
jprot.2012.03.004.
Jiang X, Shapiro DJ. The immune system and inflammation
in breast cancer. Mol Cell Endocrinol. 2014; 382:673–82.
https://doi.org/10.1016/j.mce.2013.06.003.
Pernot S, Terme M, Voron T, Colussi O, Marcheteau E,
Tartour E, Taieb J. Colorectal cancer and immunity: what
we know and perspectives. World J Gastroenterol. 2014;
20:3738–50. https://doi.org/10.3748/wjg.v20.i14.3738.
McAndrew M, Wheeler C, Anson J. Autoantibody biomarker
panels for improved disease diagnosis. In: Technology OG,
editor. 2012: 1–5.
Bolstad BM, Irizarry RA, Astrand M, Speed TP. A
comparison of normalization methods for high density
oligonucleotide array data based on bias and variance.
Bioinformatics. 2003; 19:185–93. https://doi.org/10.1093/
bioinformatics/19.2.185.
Liaw A, Wiener M. Classification and regression by random
forest. R News. 2002; 2:18–22.
Therneau T, Atkinson B, Ripley B. Package ‘rpart’. 2015.
https://cran.r-project.org/web/packages/rpart/rpart.pdf.
Kuhn M. A short introduction to the caret package. 2015.
https://cran.r-project.org/web/packages/caret/index.html.
Shapiro SS, Wilk MB. An analysis of variance for normality
(complete samples). Biometrica. 1965; 52:591–611. https://
doi.org/10.2307/2333709.

Oncotarget

